Neurotrophic Factors in clinical trials – Brief look to the recent past, present and years to come. Mart Saarma, Professor, Institute of Biotechnology, University of HelsinkiVideo (17:46 min)Slides (pdf)
Cerebral Dopamine Neurotrophic Factor (CDNF)–Potential in prevention of dopamine neuron degeneration and stimulation ofneuron regeneration. Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc Video (21:23 min)Slides (pdf)
First break with 10 min exercise. Josefa Domingos, SpecialistPhysiotherapist &EPDA Board Member Video (9:26 min)
CDNF in the first-in-human clinical trial (Safety) –12-month clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s. Magnus Sjögren, Chief Medical Officer, Herantis Pharma Plc Video (24:18 min)Slides (pdf)
CDNF in the first-in-human clinical trial (Efficacy) –12-month clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s. Per Svenningsson, Principal Investigator, Karolinska University Hospital Video (23:05 min)Slides (pdf)
Second break with 10 min exercise. Josefa Domingos, SpecialistPhysiotherapist &EPDA Board Member Video (9:11 min)
Clinical data on the investigational drug delivery system used for the CDNF infusion. Jim Baker, Head of QA/RA and Clinical Affairs, Healthcare Division, Renishaw Plc Video (17:30 min)Slides (pdf)
Panel discussion on CDNF development for Parkinson’s disease
Per Svenningsson, Professor, Principal Investigator, Karolinska University Hospital
Håkan Widner, Professor, Department of Neurology, Skåne University Hospital
Filip Scheperjans, Adjunct Professor of Neurology, Helsinki University Hospital
Juha Rinne, Professor, Turku PET Centre
Göran Lind, Neurosurgeon, Karolinska University Hospital
Paul Skinner, General Manager, Renishaw Neuro Solutions Ltd
Craig Cook, CEO, Herantis Pharma Plc
Alan Whone, Consultant Senior Lecturer in Movement Disorder, University of Bristol Video (48:16 mi
The CDNF clinical study is part of the TreatER project and has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 732386. For more information please visit the project website www.treater.eu.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.